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Abstract
The World Health Organization (WHO) estimates that there are over 50 million cases of dengue
fever reported annually and approximately 2.5 billion people are at risk. Mild dengue fever presents
with headache, fever, rash, myalgia, osteogenic pain, and lethargy. Severe disease can manifest as
dengue shock syndrome (DSS) or dengue hemorrhagic fever (DHF). Symptoms of DSS/DHF are
leukopenia, low blood volume and pressure encephalitis, cold and sweaty skin, gastrointestinal
bleeding, and spontaneous bleeding from gums and nose. Currently, there are no therapeutics
available beyond supportive care and untreated complicated dengue fever can have a 50% mortality
rate. According to WHO DSS/DHF is the leading cause of childhood mortality in some Asian
countries. Dendritic cells are professional antigen presenting cells that are primary targets in a
dengue infection. Dengue binds to Dendritic  Cell-Specific  Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN). DC-SIGN has a high affinity for ICAM3 which is expressed in
activating T-cells. Previous studies have demonstrated an altered T-cell phenotype expressed in
dengue infected patients that could be potentially mediated by dengue-infected DCs.
Dengue is enhanced by three interacting components of the immune system. Dengue begins by
infecting dendritic cells which in immature dendritic cells is mediated by DC-SIGN. In mature
dendritic cells, antibodies can enhance dengue infection via Fc receptors. Downstream of dendritic
cells T-cells become activated and generate the very cytokines implicated in vascular leak and shock
in addition to activating effector cells. Both the virus and the antibodies are involved in release of
complement and anaphylatoxins which can cause or exacerbate DHF/DSS. These systems are
inextricable and strongly associated with dengue pathogenesis.
Dengue Background and Significance
The Dengue Virus is a member of the family Flaviviridae
along with other noted viruses Yellow Fever, West Nile,
and Japanese Encephalitis. Dengue is a positive stranded
RNA arbovirus transmitted by mosquitoes typically Aedes
aegypti. Dengue fever has spread from the border lands of
Texas to South and Central America, from Africa to the
Middle East to Indonesia and Australia. The World Health
Organization (WHO) estimates between 50 million and
100 million infections every year all over the world[1].
Dengue fever will often present with fever, rash, headache,
and myalgia but can also develop into much more serious
cases of Dengue Hemorrhagic Fever and Dengue Shock
Syndrome (DHF/DSS). Cases of DHF/DSS are increasing
rapidly as the virus increases in geographic range, with
approximately 25-37% of symptomatic cases of dengue
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requiring hospitalization [2]. Case fatality rates for Den-
gue can be as high as 40-50% in untreated patients [3,4].
The dengue virus has a significant impact on the health of
those it infects and represents a burdensome cost to the
patient and health infrastructure in places that can ill
afford new and varied threats. Patients who acquire the
disease the first time (primary infections) are often
asymptomatic and will generate immunity to homolo-
gous strains of the virus; however, ninety percent of DHF/
DSS cases come from a second exposure (secondary infec-
tion) to a heterologus strain of dengue[5]. Patients with a
secondary heterotypic infection are at least 40-80 times
more likely to develop DHF/DSS as patients with a pri-
mary infection[6]. The mechanisms by which dengue
would cause severe disease are currently being elucidated,
but the prevailing literature suggests three interacting
components necessary for dengue induced immune
enhancement. One component is misregulation of cell
mediated immunity. In this context, the cross relationship
between B cells and T cells begins with dengue infection
of dendritic cells that, in turn, promiscuously activates T
cells. T cells during a dengue infection have prolific and
cross reactive effector functions in addition to producing
copious amounts of cytokines that feature prominently in
cases of DHF/DSS. A second component in immune
enhancement is Antibody Dependant Enhancement
(ADE). Heterologus non-neutralizing antibodies recog-
nize dengue epitopes and enhance infectivity in an Fc
dependant manner. Further, antibodies have been impli-
cated in an autoimmune disease which can also exacer-
bate vascular leak and cytokine production. A third
interacting component in immune activation is comple-
ment. Many of the key cytokines implicated in the
cytokine storm that characterizes DHF/DSS are regulated
by Complement proteins and associated anaphylatoxins.
These three systems both interact and reinforce each other
to create a potentially life threatening situation during a
Dengue infection.
Antibodies
Antibody Dependent Enhancement (ADE) has been pro-
posed to be a mechanism by which the immune system
may enhance viral pathogenesis[7]. When monkeys were
passively immunized concurrently with a viral infection
they developed 15 fold higher viral titers than monkeys
infected without IgG supplement[8]. However, our under-
standing of this disease is severely limited by appropriate
animal models. Animal models can support viral propa-
gation, but do not exhibit illness unless severely immuno-
compromised. Epidemiological evidence in Hawaii,
Cuba, and Thailand[9] shows populations with previous
exposure to the dengue virus are at an increased risk for
DHF/DSS. Also infants born to dengue immune mothers
were shown to be at an increased risk for DHF/DSS[10].
It's not clear how antibodies enhance viral infection. One
hypothesis suggests that non-neutralizing antibodies
direct active virions to permissive cells in the immune sys-
tem[11]. There is no "classical" enhancing antibody since
all antibodies will enhance the virus at non-neutralizing
concentrations[12]. The Fc receptor (FcR) family is a key
component in the ADE pathogenesis model. Fc receptors
are found on most phagocytes including dendritic cells
and macrophages. The FcR functions as a multisubunit
complex that typically binds to IgG and is composed of an
α chain for domain recognition, an ITAM (immunorecep-
tor tyrosine based activation motif), and a γ chain that is
responsible for signal transduction. It is thought that IgM
does not play a direct role in ADE and instead contributes
to disease pathogenesis through activation of comple-
ment receptors[13]. IgM antibody enhancement was
abrogated when C3R is blocked[14]. A hypothesis sug-
gesting that both IgG and IgM mediate viral enhancement
implies that the mechanism for ADE is multivariable. FcR
signaling pathways generally leads to activation of the
immune cell, though under certain circumstances FcR can
lead to immune modulation[15]. The normal interaction
of virus with antibody generally leads to neutralization.
However, in heterotypic dengue virus infections the anti-
bodies are non-neutralizing and lead to enhancement.
Two cell lines expressing either FcγRIA or FcγRIIA have
been used to demonstrate that immune complexes can
enhance virus infectivity in an FcR mediated fashion.
FcγRIA is found exclusively on macrophages and dendritic
cells and preferentially binds monomeric IgG, while
FcγRIIA is more broadly distributed and preferentially
binds immune complexes. When exposed to the immune
complexes containing the virus, both cell lines showed
enhanced infectivity. However, when the signaling capac-
ity of the Fc Receptor was abrogated, phagocytosis is
reduced but enhancement is not affected in FcγRIIA. In the
FcγRIA cell line, both the phagocytosis and the immune
enhancement are reduced with abrogated cell signaling.
The disparity is not yet understood. It does suggest that
viral entry and immune enhancement can be mediated by
more than a single mechanism. In a different study, three
cell types have been used to demonstrate enhance-
ment[16]. U9357 cells which express both FcγRIIA and
FcγRI have similar antibody-dependent enhancement
capabilities as K562 cells that express just FcγRII. How-
ever, the cell type Raji-1 which displays DC-SIGN instead
of the Fc receptor showed high viral titers but no antibody
enhancement.
Dendritic Cells
The putative receptor and initial target cell for the virus is
DC-SIGN (Dendritic Cell-Specific Intercellular adhesion
molecule-3 (ICAM3)-Grabbing  Non-integrin) (CD209)
on dendritic cells [17-19]. Dendritic cells are considered
crucial to fighting viral infections because of their ability
to acquire and display viral antigens that would otherwiseVirology Journal 2009, 6:211 http://www.virologyj.com/content/6/1/211
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evade the immune system. Dendritic cells affect the den-
gue virus in two ways. Immature dendritic cells express
high levels of DC-SIGN which facilitates initial viral bind-
ing and entry. While mature dendritic cells do not posses
high levels of DC-SIGN, they do facilitate ADE via FcγIIa
and FcγIIb receptors. This effect was most prominent with
serum dilutions ranging from 1:640 to 1:2,560 with com-
plete neutralization at 1:10. ADE in dendritic cells can
increase viral RNA production by over 100-fold making
dendritic cells potent components in dengue pathogene-
sis[20]. Infected dendritic cells also contribute to vascular
leak through the production of matrix metalloproteinases
(MMPs). MMP-2, MMP-13, and MMP-9 were all dramati-
cally increased in immature dendritic cells infected with
DENV2. As a result cell-cell adhesion in cells co-cultured
with infected dendritic cells was reduced, there were
changes in cell morphology and actin cytoskeleton, and a
decrease in PECAM 1 VE-cadherin expression[21].
DC-SIGN has a high affinity to the ICAM3 molecules
expressed on T-cells with a complicated system of cross
talk that can lead to a variety of outcomes[22]. To become
activated, T-cells go through a time consuming and mul-
tiphase process that lasts anywhere from 6-24 hours.
Adhesion molecules such as ICAM1 and ICAM3 are criti-
cal molecules generated by the T-cell during either phase
and can bind to the adhesion molecules of DCs particu-
larly DC-SIGN which is a known target of dengue. These
molecules are necessary to form a stable synapse between
the DC and T-cell[23]. T-cells, in turn, promote further
maturation with the expression of CD40L. Further stimu-
lation by cytokines such as TNFα, IFNγ, IL-6, and others
can rapidly promote the maturation and sensitivity of
dendritic cells. In contrast, simulation of dendritic cells
with IL-10 and other anti-inflammatory cytokines pro-
motes a regulatory phenotype for DCs[24]. Regulatory
dendritic cells have been shown to attenuate the immune
response and promote tolerance in a way analogous to T-
regulatory cells. DCs can also activate B-cells through co-
stimulation of CD40, IL-6, and IL-12. The crux of DC
interaction is in two places: DC maturation and T-cell syn-
apse. Either point represents a potential target for dengue
virus immune evasion. Should DCs fail to mature prop-
erly, they will not only fail to stimulate T-cells but they
may induce tolerance. The DC-T-cell interaction is highly
coordinated and disruption of the DC-T-cell synapse
could promote dengue pathogenesis. Dengue-specific
memory T-cells undergo simultaneous proliferation and
apoptosis during a heterotypic infection. The end result is
a less efficient and less specific T-cell response. The mech-
anism for this is unknown but given the intimacy between
DCs and T-cells this represents a potentially productive
field of research.
The role of T cells in a dengue infection
There is a clear consensus in the literature about activation
of cross-reactive memory T-cells, independent of antibody
enhancement, being a pivotal moment in the disease
process. As compelling as ADE may be, it can not fully
describe a complete picture of dengue pathogenesis such
as, intense cytokine storm[25], tissue re-modeling[26],
and effector cell activation[27]. The misregulation of T-
cells centers around the idea of Original Antigenic Sin, or
that a secondary heterotypic dengue infection can stimu-
late cross-reacting, low affinity T-cells. Activation of effec-
tor T-cells and secretion of cytokines define a key
development in course of disease associated with dengue
virus infection. Four patient studies done in Vietnam[28],
India[29], Cuba[30], and Brazil[31] all showed increases
in INFγ, TNFα, IL-10, IL-1, IL-6, IL-8, and MCP1 amongst
a variety of other cytokines. In vitro studies, IFNγ, IL-6,
TNFα, and RANTES upregulation also have been posited
as important events in dengue pathogenesis[32]. A review
of dengue-associated cytokines listed 15 different
cytokines modulated by the disease. In short, these
cytokines are consistent with widespread T-cell involve-
ment. In particular IFN and TNFα were strongly associated
with disease severity and correlate well with T-cell activa-
tion. In addition to increases in cytokine levels cellular
markers for T-cell activation, CD69, CD38, and CCR7
have been shown to be increased in dengue infection[33]
and IFNγ secretion by dengue specific T-cells has been
shown to upregulate the number of Fcγ receptors. These
receptors also play a noted role in Antibody dependant
enhancement[34].
CD8+ cells have been shown to be important in helping
control early viral infection;[35] but, the intense prolifer-
ation of CD8+ cells can also be implicated in dengue
pathogenesis[36]. In tetramer staining, peripheral T-cells
are collected from DHF patients and stained with an MHC
tetramer complexed with a dengue-specific peptide.
Tetramer positive T-cells can then be isolated and exam-
ined. When the tetramer positive cells were stained with
Ki67, they show definitive proliferation. The cells are also
found to be 'massively' apoptotic as determined by
TUNEL staining. The balance of apoptotic cells with pro-
liferative cells may skew T cell responses toward a cross-
reactive phenotype. When looking at the specific T-cells
involved in secondary infections with DENV1, many of
the T-cells show a preference for DENV3 tetramers and
infections with DENV2 show preferences in T-cells for
DENV1 and 3. Clearly, viruses are able to stimulate a vari-
ety of cross-reactive T-cell responses. Memory T-cells have
a lower activation threshold than do naïve T-cells[37] and
the low affinity non-neutralizing cells are potentially less
efficient in clearing the virus[38]. Using a similar
approach in a patient currently infected with DENV1 and
a previous infection of DENV2, scientists find that 21% ofVirology Journal 2009, 6:211 http://www.virologyj.com/content/6/1/211
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the T-cell population reacted preferentially to DENV2 and
11% were specific for DENV1[39]. Sixty-eight percent of
the T-cells in that study were fully cross-reactive between
DENV2 and DENV1. When these cells are stimulated with
DENV1 derived peptides, 51% of the cells specific for
DENV2 responded with either granulation or cytokine
release (TNFα/IFNγ) and 75-80% of the cross reactive and
DENV1 specific T-cells responded to DENV1 epitopes.
The role for the 49% of cells that demonstrate low affinity
for DENV1 and do not respond to peptide stimulation is
currently unknown, though their proliferation is certainly
suggestive. When scientists infect immune competent
mice with low dose heterologus dengue viruses they find
enhanced CD8+ T-cell responses that were dependent on
sequential viral infection as opposed to antibody
enhancement. Enhanced cell mediated immunity likely
causes target cell lysis through Perforin while bystander
cell death is mediated through Fas ligand binding[40].
There is a differential cytokine secretion in response to
antigen exposure in CD4+ cells in Dengue infected
donors. The highest IFNγ response was seen when cells
were exposed homologous antigen. The cross-reaction
IFNγ response could potential confer limited protection,
however, when cells were exposed to heterologus antigens
they produced significantly higher amounts of TNFα in
relation to IFNγ[41]. During primary infections in mice,
dengue specific CD4+ cells were low; however, in all four
viral serotypes of a secondary infection there is a marked
increase CD4+ response. Not only did CD4+ cells increase
IFNγ production, but they increased CD8+ effector cell
activation[42].
Autoimmune disorder
In addition to the antibody enhancement and T-cell dis-
ruption, autoimmune disorders are also important to
dengue pathogenesis. Anti-NS1 antibody responses in
mice have been shown to be cross-reactive in a variety of
tissues. When human anti-NS1 antibodies were devel-
oped they showed affinity for human fibrinogen, throm-
bocytes, and endothelial cells[43]. NS1 is a glycoprotein
that is secreted by infected cells, heavily present in patient
serum supernatants, lacks a membrane spanning motif,
but is not, itself, present in the virus. NS1 is known to be
a major immune target and high concentrations of anti-
NS1 antibodies have been found in severe disease in
patient studies[44]. When cells are exposed to NS1 anti-
bodies they undergo intrinsic apoptosis, characterized by
DNA fragmentation and phosphatidylserine exposure.
Bcl-2 and Bcl-x decreased and P53, Bax, and cytochrome c
increased in an iNOS dependent fashion. Apoptosis in
response to Anti-NS1 antibody treatment can be blocked
with an iNOS inhibitor[45]. The antibody mimicry is
intensely inflammatory with anti-NS1 antibodies stimu-
lating the release of IL-6, IL-8, and MCP-1 in an NFκB-
dependent manner. Correlated with antibody binding is
the upregulation of ICAM1. ICAM1 upregulation can
facilitate the adherence of PBMCs to the endothelium.
Both NFκB inhibitors and soluble NS1 to block the anti-
NS1 antibodies can able to block cytokine release in
vitro[46]. Using ELISA flow cytometry, it can be shown
that NS1 binds to the surface of uninfected cells. NS1-
binding motifs are commonly found in heparan sulfate
and chondroitin sulfate E. In mouse experiments, tissues
with a preponderance of these proteins are especially sus-
ceptible to this interaction and NS1 can be found bound
to cells in the lung and liver but not intestine or brain
endothelium of mouse tissues[47]. There is a high corre-
lation between NS1 concentration in patient sera and
high concentrations of anaphylatoxins which suggests a
role for NS1 in complement activation. Further, anaphyla-
toxins are co-localized to the lungs and plasma in dengue
infections. Co-localization experiments with membrane
bound NS1 and NS1 specific antibodies showed the for-
mation of complement attack complexes. Fluid phase
NS1 can independently activate complement. Superna-
tants collected from dengue infected cells and mixed with
normal sera shows complement activation by NS1 in a
dose dependent manner[48]. When Dengue infected
supernatants are mixed with purified antibodies from the
sera from convalescent patients infected with dengue,
complement activation is greatly enhanced. When they
added purified NS1 protein to normal or convalescent
sera they found synonymous results with NS1 activating
complement and complement activation being syner-
gized by anti-dengue antibodies. While NS1 could clearly
activate complement in the fluid phase it was unable acti-
vate complement when stably expressed on the surface of
cells. However, when patient samples were analyzed the
found a strong correlation between NS1 concentration
and C5b-C9 complex formation.
Complement activated by dengue protein and 
antibodies
The complement pathway is an ancient defense mecha-
nism designed to serve both in a sentinel capacity and in
effector function. There are three pathways to comple-
ment activation. The classical pathway begins with the for-
mation of an antibody C1q complex on the surface of a
pathogen or pathogen infected cell. This complex, in turn,
activates C2 via serine proteases and is itself also a serine
protease[49]. The protein C2a combines with newly
cleaved protein C4a to generate a C3 convertase, C2aC4b.
C3b forms the central protein complex of the comple-
ment system either by binding to complement receptors
or by complexing with C2aC4b to form C5 convertase,
C2aC4bC3b. This complex can bind and stabilize C5a
that forms the central effector function of the complement
system around which proteins C5-C9 will bind and coop-
eratively lyse the cell. The mannose binding pathway hasVirology Journal 2009, 6:211 http://www.virologyj.com/content/6/1/211
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a similar cascade as the classical pathway but functions
independently of antibody formation. Instead, MASP1
and MASP2 bind to mannose binds to the mannose struc-
tures commonly found on pathogens. The Mannan-bind-
ing lectin complex is closely homologous to C1q and can
activate C2 and C4[50]. In the absence of sialic acid sugars
present on normal somatic cells and which are rare on
pathogens, C1q begins a lytic cascade. There is a third
pathway for complement activation that begins with
spontaneous activation of complement proteins. In this
pathway the thioester bonds in C3 undergo hydrolysis
which allows the binding of Factor B and its subsequent
cleavage by plasma protease Factor D. C3b and Factor Bb
combine to form a C5 convertase. Runaway complement
activation is prevented by binding of Complement Recep-
tor 1 (CR1) and a constitutively active membrane bound
Decay Accelerating Factor (DAF, or CD55) which can pre-
vent the complement cascade[51]. In patients with severe
dengue, large amounts of C3a have been detected reveal-
ing a role for complement in dengue pathogenesis. This
finding might be anticipated by the immune complexes
that are the putative mechanism for dengue hemorrhage
and shock syndromes. C3a finds some measure of impor-
tance by being one of several anaphylatoxins produced by
complement activation capable of disrupting vasculature.
C3a serves to recruit monocytes, macrophages, and den-
dritic cells, regulates vasodilatation, and increases perme-
ability of small blood vessels and smooth muscle
contraction. In macrophages, eosinophiles, and neu-
trophils anaphylatoxins can induce oxidative burst,
basophiles, and mast cells release histamine, and C3a can
enhance the effect of other proinflammatory cytokines
such as TNFα, IL-6, and SDF-1. While the mechanism for
the many reactions precipitated by complement ana-
phylatoxins has not been fully elucidated, activation of
C3aR promotes cytokine expression through AKT phos-
phorylation as well as MAP kinase activation. C3aR is
expressed on key mediators of the immune system like
neutrophils, basophiles, eosinophiles, mast cells, mono-
cytes/macrophages, dendritic cells, microglia, as well as,
non myeloid cells like astrocytes, epithelial cells, smooth
muscles cells, and activated T-cells, but, interestingly, not
naïve T-cells. C5aR also activates a number of down-
stream signaling pathways including PI3K-γ (Phosophoi-
nosital -3 Kinase), PLC (Phospholipase C), PLD
(Phospholipase D), Raf and WASP (Wiskott-Aldrich syn-
drome protein). As a key modulator of the immune sys-
tem, complement derived proteins clearly have the
capacity to affect an extraordinarily large number of cell
types and tissues.
Anaphylatoxins
While TNF secretion and immune cell recruitment might
be appropriately devastating, the effects of anaphylatoxins
(AT) can be equally profound. C3a and C5a regulate
vasodilatation, increase permeability of blood vessels,
and can trigger degranulation and oxidative burst from
neutrophils, eosinophiles, and basophiles. C3a and C5a
act on specific receptors to produce local inflammatory
responses and when secreted in concentrations high
enough to invoke a general systemic response, they cause
circulatory collapse similar to an IgE mediated allergic
response. ATs modulate the secretion of IL-6, and TNFα
from B cells and serve as potent chemoattractants[52].
C5a also works directly on neutrophils and monocytes to
increase adhesion molecules, migration, and phagocyto-
sis. Some of the primary sources of C3 are APCs such as
dendritic cells and macrophages. Following antigenic
stimulation both DCs and T-cells upregulate C3a and C5a
receptors, produce C3, alternative complement factors B
and D, and downregulate CD55. Reduced CD55 pro-
motes T-cell proliferation and Th1 cytokine expression. In
addition to C3 production, APCs cleave C3 leading to
autocrine and paracrine C3R signaling. C3R signaling pro-
motes MHC class II expression, IL-12 production and B7
co-stimulatory molecules. Dendritic cells that fail to
express C3aR suffer reduced T-cell activation. Anaphyla-
toxins are well known initiators of inflammation but their
role in regulating APC-T cell interactions is becoming
increasingly prominent as more information is published.
The crux of dengue pathogenesis lies in misregulation of
immune processes and complement is sitting, figuratively,
at the center of multiple key pathways. Anaphylatoxins
become activated by DC antigen uptake and presentation.
Cross reactive antibodies activate complement still fur-
ther. The increase in alternative complement proteins,
complement receptors and C protein all facilitate a posi-
tive feedback loop that can have dangerous consequences
in a dengue infected patient.
Conclusion
Three immune components interact to produce a conflu-
ence of symptoms that define DHF/DSS. Dengue virus ini-
tially infects immature dendritic cells through the
mediation of DC-SIGN. Infected dendritic cells contribute
to pathogenesis through production of metalloproteases
and cytokines. Downstream of dendritic cells T-cells
become activated and generate the very cytokines impli-
cated in vascular leak and shock in addition to activating
effector cells. Antibody enhancement is mediated by Fc
receptors which are prominently on mature dendritic
cells. Viral replication mediated by antibodies is enhanced
100-fold. In addition their effects on dengue replication,
antibodies to viral epitopes cross react with cell a protein
which has the effect of stimulating CD8 effector cells and
production of cytokines and anaphylatoxins. Anaphyla-
toxins can be generated directly through viral proteins or
through formation of an antibody-complement complex.
Anaphylatoxins in turn can alter the reactivity of T-cells.
Each year 50 million people will acquire dengue fever; 2.5Virology Journal 2009, 6:211 http://www.virologyj.com/content/6/1/211
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billion people are at risk. There are few components of the
immune that are unaffected by the virus. There are yet
questions unanswered and the virus continues to spread
unabated. However these immune components are sev-
eral key elements attractive targets for study that hopefully
can advance the field of research.
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